WELCHOL- colesevelam hydrochloride tablet, film coated
WELCHOL- colesevelam hydrochloride for suspension
WELCHOL- colesevelam hydrochloride bar, chewable
Daiichi Sankyo Inc.
WELCHOL is indicated as an adjunct to diet and exercise to reduce elevated low-density lipoprotein cholesterol (LDL-C) in adults with primary hyperlipidemia.
WELCHOL is indicated to reduce LDL-C levels in boys and postmenarchal girls, 10 to 17 years of age, with heterozygous familial hypercholesterolemia (HeFH) who are unable to reach LDL-C target levels despite an adequate trial of dietary therapy and lifestyle modification.
WELCHOL is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.
- WELCHOL should not be used for the treatment of type 1 diabetes or for the treatment of diabetic ketoacidosis.
- The effect of WELCHOL on cardiovascular morbidity and mortality has not been determined.
- WELCHOL has not been studied in type 2 diabetes in combination with a dipeptidyl peptidase 4 inhibitor.
- WELCHOL has not been studied in Fredrickson Type I, III, IV, and V dyslipidemias.
- WELCHOL has not been studied in children younger than 10 years of age or in pre-menarchal girls.
Obtain lipid parameters, including TG levels and non-HDL-C, before starting WELCHOL. WELCHOL is contraindicated in patients with TG levels >500 mg/dL [see Contraindications (4) and Warnings and Precautions (5.1)].
The recommended dosage of WELCHOL for adults and children 10 to 17 years old with primary hyperlipidemia is 3.75 grams daily. The recommended dosage of WELCHOL for adults with type 2 diabetes mellitus is 3.75 grams daily. WELCHOL should be taken as follows:
Take 6 tablets once daily or 3 tablets twice daily. Due to tablet size, WELCHOL for oral suspension is recommended for use in the pediatric population.
For Oral Suspension
Take one packet once daily.
Take one bar once daily.
WELCHOL can be dosed at the same time as a statin or WELCHOL and the statin can be dosed apart. Monitor lipid levels within 4 to 6 weeks after initiation of WELCHOL.
Take WELCHOL tablets with a meal and liquid. For patients with difficulty swallowing tablets use WELCHOL for oral suspension [see Warnings and Precautions (5.2)].
For Oral Suspension:
To prepare, empty the entire contents of one packet into a glass or cup. Add 1 cup (8 ounces) of water, fruit juice, or diet soft drinks. Stir well and drink. Take WELCHOL oral suspension with meals. Do not take WELCHOL oral suspension in its dry form. Due to tablet size, WELCHOL for oral suspension is recommended for use in the pediatric population.
Take the WELCHOL chewable bar with a meal. WELCHOL chewable bars contain approximately 80 calories per bar [see Description (11)].
- Tablets: 625 mg tablets are off-white, oval, film-coated and imprinted with “Sankyo” and “C01″ on one side.
- For Oral Suspension: 3.75 gram packet containing a white to pale yellow powder with yellow granules.
- Chewable Bars: individually wrapped:
- 3.75 gram brown, rectangular, chocolate flavored bar
- 3.75 gram pink, rectangular, strawberry flavored bar
- 3.75 gram tan, rectangular, caramel flavored bar
WELCHOL is contraindicated in patients with:
- Serum TG concentrations >500 mg/dL [see Warnings and Precautions (5.1)]
- History of hypertriglyceridemia-induced pancreatitis [see Warnings and Precautions (5.1)]
- A history of bowel obstruction [see Warnings and Precautions (5.2)]
WELCHOL, like other bile acid sequestrants, can increase serum TG concentrations. Hypertriglyceridemia can cause acute pancreatitis.
WELCHOL had effects on serum TG (median increase 5% compared to placebo) in trials of patients with primary hyperlipidemia.
In trials in patients with type 2 diabetes, greater increases in TG levels occurred when WELCHOL was used as monotherapy (median increase 9.7% compared to placebo) and when WELCHOL was used in combination with pioglitazone (median increase 11% compared to placebo in combination with pioglitazone), sulfonylureas (median increase 18% compared to placebo in combination with sulfonylureas), and insulin (median increase 22% compared to placebo in combination with insulin) [see Adverse Reactions (6.1)].
Obtain lipid parameters, including TG levels and non-HDL-C, before starting WELCHOL and periodically thereafter. WELCHOL is contraindicated in patients with TG levels >500 mg/dL or patients with a history of hypertriglyceridemia-induced pancreatitis [see Contraindications (4)]. Patients with TG levels greater than 300 mg/dL could have greater increases in serum TG levels with WELCHOL and may require additional TG monitoring. Instruct patients to discontinue WELCHOL and seek prompt medical attention if the symptoms of acute pancreatitis occur (e.g., severe abdominal pain with or without nausea and vomiting). Discontinue WELCHOL if TG levels exceed 500 mg/dL [see Adverse Reactions (6.1)].
Postmarketing cases of bowel obstruction have occurred with WELCHOL [see Adverse Reactions (6.2)]. Because of its constipating effects, WELCHOL is not recommended in patients with gastroparesis, other gastrointestinal motility disorders, and in those who have had major gastrointestinal tract surgery and who may be at risk for bowel obstruction. WELCHOL is contraindicated in patients with a history of bowel obstruction [see Contraindications (4)]. Instruct patients to promptly discontinue WELCHOL and seek medical attention if severe abdominal pain or severe constipation occurs.
Because of the tablet size, WELCHOL tablets can cause dysphagia or esophageal obstruction. For patients with difficulty swallowing tablets use WELCHOL for oral suspension.
All MedLibrary.org resources are included in as near-original form as possible, meaning that the information from the original provider has been rendered here with only typographical or stylistic modifications and not with any substantive alterations of content, meaning or intent.